Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
narcolepsy
Pharma
FDA approves Takeda's first-in-class Orzeyful for narcolepsy
Takeda has scored an FDA approval for potential blockbuster Orzeyful, a first-in-class drug for adults with narcolepsy type 1.
Kevin Dunleavy
Aug 6, 2026 11:10am
Peptide adcomm Day 2: Emideltide fails to make grade in vote
Jul 24, 2026 2:00pm
Eisai taps Pokémon app for healthy sleep awareness collab
Mar 12, 2026 11:40am
With $2.37B offer, Alkermes sweetens deal to acquire Avadel
Nov 19, 2025 9:53am
Lundbeck looks to buy Avadel from under Alkermes with $2.25B bid
Nov 14, 2025 9:29am
To enter sleep market, Alkermes forks over $2.1B for Avadel
Oct 22, 2025 12:04pm
